article Why invest in creating a modifiable drug framework? 27 February 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.